EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Wan-Yu Chu iD, Om Prakash Singh iD, Shyam Sundar, Dinesh Mondal, Krishna Pandey, Pradeep Das, Ignace C Roseboom, Sheeraz Raja iD, Ana Torres iD, Eugenia Carrillo iD, Alwin D R Huitema, Fabiana Alves iD und 1 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Wan-Yu Chu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Cutaneous, Leishmaniasis, Visceral, Antiprotozoal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Dutch Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasites reside. Liposomal amphotericin B (LAmB) plays a key role in the treatment of PKDL. The mononuclear phagocyte system (MPS) is crucial in the distribution of liposomal drugs as well as the leishmaniasis pathophysiology. This study focused on characterizing the interaction between LAmB pharmacokinetics, the MPS, and parasite dynamics for optimal dosing of LAmB in PKDL. Clinical trial data from the Indian subcontinent, involving short‐course LAmB administered alone or with miltefosine, were analyzed using nonlinear mixed‐effects modeling. The pharmacokinetics of LAmB were best described by a two‐compartment model with a saturable LAmB uptake by the MPS. The maximum MPS uptake capacity was modeled with a baseline component and an additional disease‐related component relative to the parasite burden. As treatment progressed, MPS capacity decreased with declining parasite load, resulting in a median 54% increase in the systemic LAmB exposure (AUC 0‐24h ) by the end of treatment. Simulations suggested that a similar parasite clearance could be achieved with a 50% lower total LAmB dose, supporting the potential efficacy of reduced dosing regimens. Combining LAmB and miltefosine further accelerated parasite clearance compared to LAmB alone. This study highlights the importance of understanding the bidirectional interactions between LAmB pharmacokinetics and parasite infection for interpreting systemic exposure and optimizing treatment approaches. If confirmed in clinical trials, reduced LAmB dosing strategies could enable more rational and cost‐effective management of PKDL and other dermal leishmaniases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BLeishmaniasis, CutaneousLeishmaniasis, VisceralAntiprotozoal AgentsHumansAdultPhosphorylcholineMaleFemaleParasite LoadModels, BiologicalYoung AdultMiddle AgedAdolescentDrug Therapy, CombinationDose-Response Relationship, Drug

Substanzen

Amphotericin Bliposomal amphotericin BAntiprotozoal AgentsPhosphorylcholinemiltefosine

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.
  • Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Kala-azar Medical Research Center (KARMC), Muzaffarpur, India.
  • International Centre for Diarrhoeal Disease Research, (icddr,b), Dhaka, Bangladesh.

ORCID-Profile: Wan-Yu Chu, Om Prakash Singh, Sheeraz Raja, Ana Torres, Eugenia Carrillo, Fabiana Alves, Thomas P C Dorlo

Förderung

  • Swedish Research Council
  • Dutch Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Vetenskapsrådet

Zitieren

APA

Chu, W. Y., Singh, O. P., Sundar, S., Mondal, D., Pandey, K., Das, P., Roseboom, I. C., Raja, S., Torres, A., Carrillo, E., Huitema, A. D. R., Alves, F., & Dorlo, T. P. C. (2026). Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70124

Vancouver

Chu WY, Singh OP, Sundar S, Mondal D, Pandey K, Das P, et al. Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70124

BibTeX
@article{Chu2026,
  author = {Chu, Wan-Yu and Singh, Om Prakash and Sundar, Shyam and Mondal, Dinesh and Pandey, Krishna and Das, Pradeep and Roseboom, Ignace C and Raja, Sheeraz and Torres, Ana and Carrillo, Eugenia and Huitema, Alwin D R and Alves, Fabiana and Dorlo, Thomas P C},
  title = {Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70124}
}
Kostenlos starten →